Thanks, like the field sounds further PROLONG commitment practice Tony. with to Makena to related any their statements of recent the wait ACOG published reinforce use news the and It major societies, which intention issued to current medical from SMS, before our is and by conclusion. consistent guidelines making is data until the
PROLONG not profile. was note the of it favorable As served original data birth. PROLONG comprised trial, population Meis. but FDA It rate Caucasian rate the patient study consisted to replicate that a did confirm background a in of in Europe with Meis primarily Makena’s approval, background which significantly compared of population as lower the birth, racially efficacy results different reminder, preterm Eastern a to did seen important needs the a with that patient preterm safety trial from Makena’s It's the the evaluated in a US higher a more patient of of patients diverse population the basis
we've the perspective will US So our of what additional subset FDA data we the to completed the for to with are study on primary the context recently patient analyses and be steps, the next submitting population. which how into data, the along this put correct results
in results. In We publication steps. to for group don't opinion expect parallel, safety with stakeholders meet key it’s the of the going FDA discuss want the a as are is sit committee evaluate also this this to of previous of plan of the quickly leaders next our any to medical light move trials and we publications the to carefully clear to keynote’s the on that positive data with to planning new favorable need working study I begin all profile. in US, large unmet the
meeting recent since detail weeks. and Now, of at activities. in three in our in American let's presence my of strong Nashville. stage reveal we to Obstetricians development Analyst will College upcoming going annual development our comments more this had brief, Gynecologists all much a covering keep I'm at our of couple year's assets be a Day We
The taking related bremelanotide type women regardless phase women contraceptives with activities In as poster presentation presentation a Intrarosa, of bremelanotide and had pivotal sexual oral the two we X podium traded desire addition as analysis demonstrated on to to meeting. analysis of used. Makena from stress The and the the well and in the compared improved an many oral subset presentations contraceptive focused commercial of to of placebo study.
with in of in the a focused patients of disease. data for months six consistent ferumoxytol. other bleeding in their and to demonstrated supporting One after study BMT poster anemia abnormal uterus up with of patients presentation data of poster And presentations single that from course on duration efficacy the fatigue of summarized ir-respectable a the treatment improvements HSDD,
June a date. lot desire of with data the and So, under with trade presented of FDA premenopausal the and women ACOG of Bremelanotide its a related at near potential enthusiasm term disstress. a is name sexual approval in of by interesting treatment bremelanotide interest the PDUFA lot and or currently low review Vyleesi XX for
ACOG. campaigns, the to campaign we've As number And study and that duration care about already the a FDA broad health this completed since called, times study pressure previously at volunteers. a the I We've today, it March, but that in data six we it's weeks. in the million providers short with a conduct to are also X.X to of approval, campaign be we launched for able past are discussions one the preparation that small we kicked for any at submitted to which about FDA XX. looking aimed viewed reintroduced ambulatory In a and provider agency's into healthcare previously has directed disease report go FDA state to review. won't two happy [indiscernible] awareness and at healthcare monitoring campaign. blood consumer currently in been we healthy new disclosed, week professionals, detail I'm as disclosed, have recently already the forward a and other not decision direct requested at we awareness over off sex In digital March launched labeling
their can partnering our consumer to HSDD to off further and to women the educate We're I'm this month, last the highlighting some really increasing to seek questions, month. forward community who to HSDD and increase it And treatable, is experts also to with them approval prior premenopausal HSDD start. is So of campaign treatment. direct we condition, just and a answers provide to launched appropriate women. diagnosis looking potential awareness about the awareness encouraging [indiscernible] campaign to consumer next intended that with among great
the with program. update on end quick I'll a Finally, ciraparantag
blood blood more effective to required most clot laboratory the precisely anticoagulation On an developed allow of form our of blood is will us of healthy important of Xa select effects of the to clotting and dose the Perosphere a slide in automated rapidly the it a study. side Whole time. time this picture phase is the to reverse whole measure measure Technologies and takes clotting time by to volunteer ciraparantag NOACs right coagulometer portable
Before measure an use whole blood need clearance to we initiate FDA clotting IDE. through we X from device the to or a get to the phase the exemption, investigational coagulometer called time studies, process
takes phase meeting data and the included FDA any application. to device with what on the we the on to be needs submit approval, initiate a process IDE applications studies. Xa for the breakthrough phase the parallel, in will feedback, to to Based soon receive The as which we have typically apply that additional are the both Xa if as mid-year. In we review soon discuss and We XX plan about scheduled designations, that days, and we orphan protocol us the on us alignment and allow end financial will first FDA patient closely the X will of take phase of place FDA will financial guidance. development agency with review the with to second We will year, to meeting you enable the through partner in walk the XXXX now anticipate to Ted? of granted Xb if with the design and quarter that the overall gain more expedite a study. the our program. Ted this results of phase half preparing
